Towards this end, optimization of pharmacologic therapy to effect RIPK3 demethylation may represent a novel therapeutic intervention that facilitates improved outcomes in pediatric patients with chemo resistant osteosarcoma. Here, RIPK3 is linked to osteosarcoma.